Logo image of NEW

PUXIN LTD-ADR (NEW) Stock Fundamental Analysis

NYSE:NEW - New York Stock Exchange, Inc. - US74704P4054 - ADR

1.36  +0.08 (+6.25%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to NEW. NEW was compared to 71 industry peers in the Diversified Consumer Services industry. NEW has a bad profitability rating. Also its financial health evaluation is rather negative. NEW is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NEW had positive earnings in the past year.
NEW Yearly Net Income VS EBIT VS OCF VS FCFNEW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 0 -200M -400M -600M -800M

1.2 Ratios

Industry RankSector Rank
ROA 1.02%
ROE 10.46%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NEW Yearly ROA, ROE, ROICNEW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 0 100 -100 200

1.3 Margins

Industry RankSector Rank
OM -5.97%
PM (TTM) 1.73%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NEW Yearly Profit, Operating, Gross MarginsNEW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 0 20 -20 40

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, NEW has more shares outstanding
NEW has a worse debt/assets ratio than last year.
NEW Yearly Shares OutstandingNEW Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 200M 400M 600M 800M
NEW Yearly Total Debt VS Total AssetsNEW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 1B 2B 3B 4B

2.2 Solvency

NEW has an Altman-Z score of -0.29. This is a bad value and indicates that NEW is not financially healthy and even has some risk of bankruptcy.
NEW has a Debt/Equity ratio of 1.43. This is a high value indicating a heavy dependency on external financing.
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF N/A
Altman-Z -0.29
ROIC/WACCN/A
WACCN/A
NEW Yearly LT Debt VS Equity VS FCFNEW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 0 200M -200M 400M 600M

2.3 Liquidity

NEW has a Current Ratio of 0.39. This is a bad value and indicates that NEW is not financially healthy enough and could expect problems in meeting its short term obligations.
A Quick Ratio of 0.38 indicates that NEW may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.39
Quick Ratio 0.38
NEW Yearly Current Assets VS Current LiabilitesNEW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 1B 2B 3B

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 113.26% over the past year.
Looking at the last year, NEW shows a very negative growth in Revenue. The Revenue has decreased by -12.35% in the last year.
The Revenue has been growing by 60.35% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)113.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%186.7%
Revenue 1Y (TTM)-12.35%
Revenue growth 3Y31.31%
Revenue growth 5Y60.35%
Sales Q2Q%-8.59%

3.2 Future

NEW is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -5.61% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-91.96%
EPS Next 2Y-51.74%
EPS Next 3Y-29.84%
EPS Next 5Y-5.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NEW Yearly Revenue VS EstimatesNEW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 1B 2B 3B
NEW Yearly EPS VS EstimatesNEW Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 136.00, the valuation of NEW can be described as expensive.
The average S&P500 Price/Earnings ratio is at 27.45. NEW is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 1.50, the valuation of NEW can be described as very cheap.
The average S&P500 Price/Forward Earnings ratio is at 21.90. NEW is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 136
Fwd PE 1.5
NEW Price Earnings VS Forward Price EarningsNEW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -24.8
NEW Per share dataNEW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

A cheap valuation may be justified as NEW's earnings are expected to decrease with -29.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-51.74%
EPS Next 3Y-29.84%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NEW!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PUXIN LTD-ADR

NYSE:NEW (5/3/2022, 8:22:04 PM)

1.36

+0.08 (+6.25%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)03-14 2022-03-14/bmo
Earnings (Next)05-23 2022-05-23
Inst Owners0.32%
Inst Owner Change-90.6%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap118.95M
Analysts84
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 136
Fwd PE 1.5
P/S 0.28
P/FCF N/A
P/OCF N/A
P/B 1.72
P/tB N/A
EV/EBITDA -24.8
EPS(TTM)0.01
EY0.74%
EPS(NY)0.91
Fwd EY66.58%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS4.78
BVpS0.79
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.02%
ROE 10.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -5.97%
PM (TTM) 1.73%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.39
Quick Ratio 0.38
Altman-Z -0.29
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)113.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%186.7%
EPS Next Y-91.96%
EPS Next 2Y-51.74%
EPS Next 3Y-29.84%
EPS Next 5Y-5.61%
Revenue 1Y (TTM)-12.35%
Revenue growth 3Y31.31%
Revenue growth 5Y60.35%
Sales Q2Q%-8.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A